# Duloxetine for Multiple Sclerosis Pain

> **NCT00755807** · PHASE3 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 239 (actual)

## Conditions studied

- Multiple Sclerosis

## Interventions

- **DRUG:** Duloxetine Hydrochloride (HCI)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00755807
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-10
- **Primary completion:** 2010-08
- **Final completion:** 2010-11
- **Target enrollment:** 239 (ACTUAL)
- **Last updated:** 2011-12-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00755807

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00755807, "Duloxetine for Multiple Sclerosis Pain". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00755807. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*